This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Urich, S. K.
Right arrow Articles by Petersen, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Urich, S. K.
Right arrow Articles by Petersen, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2276-2278, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01584-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibility of Isolates of Francisella tularensis Types A and B from North America{triangledown}

Sandra K. Urich and Jeannine M. Petersen*

Bacterial Diseases Branch, Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado

Received 7 December 2007/ Returned for modification 9 March 2008/ Accepted 5 April 2008

Due to concern that Francisella tularensis, the causative agent of tularemia, may be used as a bioterrorist weapon, the Clinical and Laboratory Standards Institute recently provided a susceptibility testing method with breakpoints. Here, 169 isolates (92 type A and 77 type B) from North America were tested against seven antimicrobial agents (streptomycin, gentamicin, tetracycline, doxycycline, ciprofloxacin, levofloxacin, and chloramphenicol) used for the treatment of tularemia. The MICs for all of the isolates fell within the susceptible range. In addition, all isolates had MICs for erythromycin of 0.5 to 4 µg/ml, in contrast to an MIC of >256 µg/ml for the common laboratory strain LVS (live vaccine strain).

* Corresponding author. Mailing address: Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Foothills Campus, 3150 Rampart Road, Ft. Collins, CO 80521. Phone: (970) 266-3524. Fax: (970) 494-6631. E-mail: nzp0{at}cdc.gov

{triangledown} Published ahead of print on 14 April 2008.

Antimicrobial Agents and Chemotherapy, June 2008, p. 2276-2278, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01584-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»